


Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application.

Listing of Claims:

Claim 1. (currently amended) A pharmaceutical composition containing method for suppressing the number of peripheral blood lymphocytes comprising administering to a human in need thereof a pharmaceutically effective amount of a compound having a general formula (I):
{Chemical Formula 1}



[[()]]wherein R¹ represents a methyl group or an ethyl group, R² represents a methyl group or an ethyl group, and R³ represents a phenyl group substituted with 1 to 3 substituents selected from the group consisting of a halogen atom, a lower alkyl group, a cycloalkyl group, a lower alkoxy group, a halogeno lower alkyl group, a lower aliphatic acyl group and a cyano group[[()]], a pharmacologically acceptable salt thereof or a pharmacologically acceptable ester thereof.

Claim 2. (currently amended) [[A]] pharmaceutical composition The method according to claim 1, wherein R¹ is a methyl group.

Claim 3. (currently amended) [[A]] pharmaceutical composition The method according to claim 1 [[or 2]], wherein R² is a methyl group.

Claim 4. (currently amended) [[A]] pharmaceutical composition The method according to any of claims claim 1 [[to 3]], wherein R³ is a phenyl group substituted with 1 to 3 substituents selected from the group consisting of a lower alkyl group, a cycloalkyl group and a lower alkoxy group.

Claim 5. (currently amended) [[A]] pharmaceutical composition The method according to any of claims claim 1 [[to 3]], wherein R³ is a phenyl group substituted with 1 to 3 substituents selected from the group consisting of a lower alkyl group and a lower alkoxy group.

Claim 6. (currently amended) [[A]] pharmaceutical composition The method according to any of claims claim 1 [[to 3]], wherein R³ is a phenyl group substituted with 1 to 3 substituents selected from the group consisting of a methyl group and a methoxy group.

Claim 7. (canceled)

Claim 8. (currently amended) [[A]] pharmaceutical composition The method according to any of claims claim 1 [[to 7]], wherein the pharmacologically acceptable salt is administered and the pharmacologically acceptable salt is a fumarate.

Claims 9 to 17. (canceled)

Claim 18. (currently amended) [[A]] pharmaceutical composition The method according to any of claims claim 1 [[to 17]] for administering, wherein the compound is orally administered to a human [[adults]] adult at a dose of [[the]] active ingredient [[of]] 0.0001 mg/kg/day to 1 mg/kg/day.

Claim 19. (new) The method according to claim 1, wherein the compound is (2R)-2-amino-2-methyl-4-{1-methyl-5-[4-(3-methylphenyl)butanoyl]pyrrol-2-yl}butan-1-ol] or a pharmacologically acceptable salt or a pharmacologically acceptable ester thereof.

Claim 20. (new) The method according to claim 1, wherein the compound is (2R)-2-amino-2-methyl-4-{1-methyl-5-[4-(4-methylphenyl)butanoyl]pyrrol-2-yl}butan-1-ol or a pharmacologically acceptable salt or a pharmacologically acceptable ester thereof.

Claim 21. (new) The method according to claim 1, wherein the compound is (2R)-2-amino-2-methyl-4-{1-methyl-5-[4-(3,4-dimethylphenyl)butanoyl]pyrrol-2-yl}butan-1-ol or a pharmacologically acceptable salt or a pharmacologically acceptable ester thereof.

Claim 22. (new) The method according to claim 1, wherein the compound is (2R)-2-amino-2-methyl-4-{1-methyl-5-[4-(4-methoxyphenyl)butanoyl]pyrrol-2-yl}butan-1-ol or a pharmacologically acceptable salt or a pharmacologically acceptable ester thereof.

Claim 23. (new) The method according to claim 1, wherein the compound is (2R)-2-amino-2-methyl-4-{1-methyl-5-[4-(3-methyl-4-methoxyphenyl)butanoyl]pyrrol-2-yl}butan-1-ol or a pharmacologically acceptable salt or a pharmacologically acceptable ester thereof.

Claim 24. (new) A fumarate salt of a compound selected from the group consisting of

(2R)-2-amino-2-methyl-4-{1-methyl-5-[4-(3-methylphenyl)butanoyl]pyrrol-2-yl}butan-1-ol,
(2R)-2-amino-2-methyl-4-{1-methyl-5-[4-(4-methylphenyl)butanoyl]pyrrol-2-yl}butan-1-ol,
(2R)-2-amino-2-methyl-4-{1-methyl-5-[4-(3,4-dimethylphenyl)butanoyl]pyrrol-2-yl}butan-1-ol,
(2R)-2-amino-2-methyl-4-{1-methyl-5-[4-(4-methoxyphenyl)butanoyl]pyrrol-2-yl}butan-1-ol and
(2R)-2-amino-2-methyl-4-{1-methyl-5-[4-(3-methyl-4-methoxyphenyl)butanoyl]pyrrol-2-yl}butan-1-ol.

Claim 25. (new) The fumarate salt according to claim 24, wherein the compound is (2R)-2-amino-2-methyl-4-{1-methyl-5-[4-(3-methylphenyl)butanoyl]pyrrol-2-yl}butan-1-ol.

Claim 26. (new) The fumarate salt according to claim 24, wherein the compound is (2R)-2-amino-2-methyl-4-{1-methyl-5-[4-(4-methylphenyl)butanoyl]pyrrol-2-yl}butan-1-ol.

Claim 27. (new) The fumarate salt according to claim 24, wherein the compound is (2R)-2-amino-2-methyl-4-{1-methyl-5-[4-(3,4-dimethylphenyl)butanoyl]pyrrol-2-yl}butan-1-ol.

Claim 28. (new) The fumarate salt according to claim 24, wherein the compound is (2R)-2-amino-2-methyl-4-{1-methyl-5-[4-(4-methoxyphenyl)butanoyl]pyrrol-2-yl}butan-1-ol.

Claim 29. (new) The fumarate salt according to claim 24, wherein the compound is (2R)-2-amino-2-methyl-4-{1-methyl-5-[4-(3-methyl-4-methoxyphenyl)butanoyl]pyrrol-2-yl}butan-1-ol.

Claim 30. (new) A pharmaceutical composition comprising a pharmaceutically effective amount of the fumarate salt according to claim 24 in combination with a pharmaceutically acceptable carrier.

Claim 31. (new) A method for suppressing the number of peripheral blood lymphocytes comprising administering to a warm-blooded animal in need thereof a pharmaceutically effective amount of the fumarate salt according to claim 24.

Claim 32. (new) The method according to claim 31, wherein the warm-blooded animal is a human.

Claim 33. (new) The method according to claim 32, wherein the fumarate salt is orally administered to a human adult at a dose of 0.0001 mg/kg/day to 1 mg/kg/day.

Claim 34. (new) A method for suppressing rejection of a skin transplant or an organ transplant comprising administering to a warm-blooded animal in need thereof a pharmaceutically effective amount of the fumarate salt according to claim 24.

Claim 35. (new) The method according to claim 34, wherein the warm-blooded animal is a human.

Claim 36. (new) The method according to claim 35, wherein the fumarate salt is orally administered to a human adult at a dose of

0.0001 mg/kg/day to 1/mg/kg/day.

Claim 37. (new) A method for treating or preventing an autoimmune disease or an immunity related disease comprising administering to a warm-blooded animal in need thereof a pharmaceutically effective amount of the fumarate salt according to claim 24.

Claim 38. (new) The method according to claim 37, wherein the warm-blooded animal is a human.


Claim 39. (new) The method according to claim 38, wherein the disease is selected from the group consisting of systemic lupus erythematosus, rheumatoid arthritis, polymyositis, fibrositis, skeletal myositis, arthrosteitis, osteoarthritis, dermatomyositis, scleroderma, Behcet's disease, Crohn's disease, ulcerative colitis, autoimmune hepatitis, aplastic anemia, idiopathic thrombocytopenic purpura, autoimmune hemolytic anemia, multiple sclerosis, autoimmune pomphus, psoriasis vulgaris, angiitis, Wegener's granuloma, uveitis, Sjogren's syndrome, idiopathic interstitial pneumonia, Goodpasture's syndrome, sarcoidosis, allergic granulomatous angiitis, bronchial asthma, myocarditis, cardiomyopathy, aortitis syndrome, postmyocardial infarction syndrome, primary pulmonary hypertension, lipoid nephrosis, membranous nephropathy, membranoproliferative glomerulonephritis, focal glomerular sclerosis, crescentic nephritis, myasthenia gravis, inflammatory neuropathy, atopic dermatitis, chronic photosensitive dermatitis, hyperphotosensitivity, decubitis ulcer, Sydenham's chorea, sclerosis, adult-onset diabetes, insulin-dependent diabetes, juvenile diabetes, atherosclerosis, glomerulonephritis, IgA nephropathy, tubulointerstitial nephritis, primary biliary cirrhosis, primary sclerosing cholangitis, fulminant hepatitis, viral hepatitis, GVHD,

contact dermatitis, septicemia, a fungal infection, a mycoplasma infection, a viral infection, a protozoan infection, cardiac failure, cardiomegaly, arrhythmia, angina pectoris, cardiac ischemia, arterial embolism, aneurysm, varix, a circulatory disorder, Alzheimer's disease, dementia, Parkinson's disease, stroke, cerebral infarction, cerebral ischemia, depression, manic depression, schizophrenia, Huntington's chorea, epilepsy, convulsion, hyperactivity disorder, encephalitis, meningitis, anorexia, bulimia, lymphoma, leukemia, polyuria, thamuria and diabetic retinopathy.

Claim 40. (new) The method according to claim 39, wherein the disease is selected from the group consisting of systemic lupus erythematosus, rheumatoid arthritis, psoriasis, atopic dermatitis, multiple sclerosis, ulcerative colitis and Crohn's disease.

Claim 41. (new) The method according to claim 40, wherein the fumarate salt is orally administered to a human adult at a dose of 0.0001 mg/kg/day to 1 mg/kg/day.

Claim 42. (new) A method for suppressing the number of peripheral blood lymphocytes comprising administering to a warm-blooded animal in need thereof a pharmaceutically effective amount of a compound having a formula (I):



wherein R¹ represents a methyl group or an ethyl group, R² represents a methyl group or an ethyl group, and R³ represents a phenyl group substituted with 1 to 3 substituents selected from the group consisting of a halogen atom, a lower alkyl group, a cycloalkyl group, a lower alkoxy group, a halogeno lower alkyl group, a lower aliphatic acyl group and a cyano group, a pharmacologically acceptable salt thereof or a pharmacologically acceptable ester thereof.